Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 12
Submit an article Journal homepage
248
Views
10
CrossRef citations to date
0
Altmetric
Review

Management of incomplete remission and treatment resistance in first-episode psychosis

Martin Lambert University Medical Centre Hamburg-Eppendorf, Psychosis Early Detection and Intervention Centre, Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, Martinistreet 52, D-20246 Hamburg, Germany +49 40 42803 7670; +49 40 42803 5455; [email protected]
,
Dieter Naber University Medical Centre Hamburg-Eppendorf, Psychosis Early Detection and Intervention Centre, Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, Martinistreet 52, D-20246 Hamburg, Germany +49 40 42803 7670; +49 40 42803 5455; [email protected]
&
Christian G Huber University Medical Centre Hamburg-Eppendorf, Psychosis Early Detection and Intervention Centre, Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, Martinistreet 52, D-20246 Hamburg, Germany +49 40 42803 7670; +49 40 42803 5455; [email protected]
Pages 2039-2051 | Published online: 31 Jul 2008

Bibliography

  • Huber CG, Naber D, Lambert M. Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors. Expert Opin Pharmacother 2008;9(12):2027-38
  • Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63(10):892-909
  • Lindenmayer JP, Khan A. Pharmacological treatment strategies for schizophrenia. Expert Rev Neurother 2004;4(4):705-23
  • Buckley PF, Wiggins LD, Sebastian S, Singer B. Treatment-refractory schizophrenia. Curr Psychiatry Rep 2001;3(5):393-400
  • Schimmelmann BG, Conus P, Edwards J, et al. Diagnostic stability 18 months after treatment initiation for first-episode psychosis. J Clin Psychiatry 2005;66(10):1239-46
  • Andreasen NC, Carpenter WT JR, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162(3):441-9
  • Liberman RP, Kopelowicz A. Recovery from schizophrenia: a concept in search of research. Psychiatr Serv 2005;56:735-42
  • Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006;11:227-40
  • Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007;52:46-54
  • Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999;60(Suppl 22):7-11
  • Nierenberg AA, Dececco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):5-9
  • National Institute for Clinical Excellence (editors). Clinical Guideline 1 Schizophrenia Core Interventions in the Treatment and Mangement of Schizophrenia in Primary and Secondary Care. London: National Institute for Clinical Excellence; 2002
  • American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. In: American Psychiatric Association, editors, Practice Guidelines for the treatment of psychiatric disorders, Compendium 2004. 2nd edition. Arlington, VA: American Psychiatric Publishing; 2004. p. 249-440
  • Royal Australian and New Zealand College of Psychiatrists. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005;39(1/2):1-30
  • American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. In: American Psychiatric Association, editors, Practice Guidelines for the treatment of psychiatric disorders, Compendium 2004. 2nd edition. Arlington, VA: American Psychiatric Publishing; 2004. p. 525-612
  • Royal Australian And New Zealand College Of Psychiatrists. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry 2004;38(5):280-305
  • American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. In: American Psychiatric Association, editors, Practice Guidelines for the treatment of psychiatric disorders, Compendium 2004. 2nd edition. Arlington, VA: American Psychiatric Publishing; 2004. p. 440-524
  • Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004;61:669-80
  • Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005;112(2):141-8
  • Lambert M, Conus P, Naber D, et al. Olanzapine in subjects with a first-episode psychosis non-responsive, intolerant or non-compliant to a first-line trial of risperidone. Int J Psychiatry Clin Pract 2005;9(4):244-50
  • Lambert M, Conus P, Schimmelmann BG, et al. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study. Pharmacopsychiatry 2005;38(5):206-13
  • Pantelis C, Lambert TJ. Managing patients with ‘treatment-resistant’ schizophrenia. Med J Aust 2003;178(Suppl):S62-6
  • Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-9
  • Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther 2004;26(12):1994-2002
  • Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160(6):1125-32
  • Buckley PF, Goldstein JM, Emsley RA. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res 2004;66(2/3):143-50
  • Lindenmayer JP, Czobor P, Volavka J, et al. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J Clin Psychiatry 2002;63(10):931-5
  • Lambert M, Naber D, editors. Current schizophrenia. Hamburg: Science Press; 2004
  • Semiz UB, Cetin M, Basoglu C, et al. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(6):1330-6
  • Umbricht DS, Wirshing WC, Wirshing DA, et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry 2002;63(5):420-4
  • Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158(4):518-26
  • Ciapparelli A, Dell'osso L, Bandettini Di Poggio A, et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003;64(4):451-8
  • Pickar D, Bartko JJ. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia. Am J Psychiatry 2003;160(6):1133-8
  • Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159(2):255-62
  • Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19(10):843-72
  • Fabrazzo M, La Pia S, Monteleone P, et al. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology 2002;27(6):1050-5
  • Miller DD. Review and management of clozapine side effects. J Clin Psychiatry 2000;61(Suppl 8):14-7; discussion 18-9
  • Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005;20(5/6):409-15
  • Williams L, Newton G, Roberts K, et al. Clozapine-resistant schizophrenia: a positive approach. Br J Psychiatry 2002;181:184-7
  • Kämpf P, Agelink MW, Mas R, et al. Amisulpride in addition to clozapine: a retrospective study indicates improved efficacy and good tolerability. German J Psychiatry 2003;6(3):64-8
  • Kalyoncu A, Mirsal H, Pektas O, et al. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J Psychopharmacol 2005;19(3):301-5
  • Lerner V, Bergman J, Borokhov A, et al. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol 2005;28(2):66-71
  • Lerner V, Libov I, Kotler M, Strous RD. Combination of ‘atypical’ antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004;28(1):89-98
  • Lerner V, Chudakova B, Kravets S, Polyakova I. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol 2000;23(5):284-6
  • Valmaggia LR, Van Der Gaag M, Tarrier N, et al. Cognitive–behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. Randomised controlled trial. Br J Psychiatry 2005;186:324-30
  • Sensky T, Turkington D, Kingdon D, et al. A randomized controlled trial of cognitive–behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch Gen Psychiatry 2000;57(2):165-72
  • Fitzgerald PB, Benitez J, Daskalakis JZ, et al. A double-blind sham-controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. J Clin Psychopharmacol 2005;25(4):358-62
  • Perlis RH. The role of pharmacologic treatment guidelines for bipolar disorder. J Clin Psychiatry 2005;66(Suppl 3):37-47
  • Bowden CL. Treatment options for bipolar depression. J Clin Psychiatry 2005;66(Suppl 1):3-6
  • Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161(9):1537-47
  • Kilzieh N, Akiskal HS. Rapid-cycling bipolar disorder. An overview of research and clinical experience. Psychiatr Clin North Am 1999;22(3):585-607
  • Colom F, Vieta E. A perspective on the use of psychoeducation, cognitive–behavioral therapy and interpersonal therapy for bipolar patients. Bipolar Dis 2004;6(6):480-6
  • Perry A, Tarrier N, Morriss R, et al. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ 1999;318(7177):149-53
  • Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003;60(4):402-7
  • Vieta E. The package of care for patients with bipolar depression. J Clin Psychiatry 2005;66(Suppl 5):34-9
  • Miklowitz DJ, Simoneau TL, George EL, et al. Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy. Biol Psychiatry 2000;48(6):582-92
  • Ros S, Aguera L, De La Gandara J, et al. Potentiation strategies for treatment-resistant depression. Acta Psychiatr Scand Suppl 2005;(428):14-24, 36
  • Quitkin FM, Mcgrath PJ, Stewart JW, et al. Can the effects of antidepressants be observed in the first two weeks of treatment? Neuropsychopharmacology 1996;15(4):390-4
  • Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry 2001;62(Suppl 18):12-7
  • Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001;46(Suppl 1):38S-58S
  • Kennedy JS, Jeste D, Kaiser CJ, et al. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Int J Geriatr Psychiatry 2003;18(11):1013-20
  • Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 18):4-11
  • Rojo JE, Ros S, Aguera L, et al. Combined antidepressants: clinical experience. Acta Psychiatr Scand Suppl 2005;(428):25-31, 36
  • Klein N, Sacher J, Wallner H, et al. Therapy of treatment resistant depression: focus on the management of TRD with atypical antipsychotics. CNS Spectr 2004;9(11):823-32
  • Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005;66(Suppl 8):30-40
  • Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 2005;66(Suppl 8):13-21
  • Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005;66(10):1216-20
  • Malhi GS, Berk M, Bourin M, et al. A typical mood stabilizers: a ‘typical’ role for atypical antipsychotics. Acta Psychiatr Scand Suppl. 2005;(426):29-38
  • Thase ME. Treatment of severe depression. J Clin Psychiatry 2000;61(Suppl 1):17-25
  • Mcpherson S, Cairns P, Carlyle J, et al. The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. Acta Psychiatr Scand 2005;111(5):331-40
  • Avery DH, Holtzheimer PE III, Fawaz W, et al. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol Psychiatry 2006;59(2):187-94
  • Rossini D, Lucca A, Zanardi R, et al. Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial. Psychiatry Res 2005;137(1/2):1-10
  • Nahas Z, Marangell LB, Husain MM, et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005;66(9):1097-104

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.